NCT06640673 Electrophysiological Signature of Mild Cognitive Impairment and Its Relationship with Parkinson's Disease: a High-density EEG Investigation
| NCT ID | NCT06640673 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS San Camillo, Venezia, Italy |
| Condition | Parkinson Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 42 participants |
| Start Date | 2023-06-18 |
| Primary Completion | 2024-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 42 participants in total. It began in 2023-06-18 with a primary completion date of 2024-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to investigate neural correlate of Mild Cognitive Impairment (MCI) in Parkinson's disease (PD) and to identify a link between functional impairment (in both cognitive and motor domains) and electrophysiological cortical sing of MCI in PD. A sample of 42 subjects will be divide into three subgroup: healthy control, PD with MCI (PD-MCI) and PD without MCI (PD-ctrl). Those subjects will undergo a specific neuropsychological evaluation and, to measure the electro-cortical activity, high-density electroencephalography (hdEEG) will be record during both resting state and cognitive tasks. Furthermore, hdEEG data will be combine with structural magnetic resonance to obtain information about network connectivity.
Eligibility Criteria
Inclusion Criteria: * Upper score \>24 MMSE or \>15.5 Moca * If taking medications, taking stable doses for at least 4 weeks prior to the inclusion visit - of anticholinesterase drugs (donepezil, memantine, rivastigmine, ...) or antidepressants (SSRIs, tricyclics, SNARI, ...) or Levodopa. * Having signed the informed consent Exclusion Criteria: * Subjects with severe dementia ( MMSE \< 24 ) * Lower score \<15.5 Moca * Subjects on antipsychotic treatment for less than 3 months * Subjects with uncontrolled comorbidities * Subjects with metal prostheses or dentures and in general conditions for which MRI examinations are prevented. * Subjects with an inability to walk independently.
Contact & Investigator
francesca burgio, phd
PRINCIPAL INVESTIGATOR
San Camillo IRCCS
Frequently Asked Questions
Who can join the NCT06640673 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 90 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06640673 currently recruiting?
Yes, NCT06640673 is actively recruiting participants. Contact the research team at francesca.burgio@hsancamillo.it for enrollment information.
Where is the NCT06640673 trial being conducted?
This trial is being conducted at Lido, Italy.
Who is sponsoring the NCT06640673 clinical trial?
NCT06640673 is sponsored by IRCCS San Camillo, Venezia, Italy. The principal investigator is francesca burgio, phd at San Camillo IRCCS. The trial plans to enroll 42 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.